Dynamic tumor modeling of the dose–response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial
Open Access
- 23 July 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 12 (1), 311
- https://doi.org/10.1186/1471-2407-12-311
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- mTOR pathway inhibition in renal cell carcinomaUrologic Oncology: Seminars and Original Investigations, 2012
- The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastasesCancer, 2010
- Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapyJournal of Hematology & Oncology, 2009
- EverolimusDrugs, 2009
- Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor DynamicsJournal of Clinical Oncology, 2009
- Exploring the pathogenesis of renal cell carcinoma: pathway and bioinformatics analysis of dysregulated genes and proteinsBiological Chemistry, 2008
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2008
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2008
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000